Pacira BioSciences to Present at the 44th Annual J.P. Morgan Healthcare Conferences
Rhea-AI Summary
Pacira BioSciences (Nasdaq: PCRX) will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 11:15 AM PST (2:15 PM EST). Live audio will be available via the company’s Events page at investor.pacira.com. A replay of the webcast will be accessible for two weeks following the presentation.
This presentation offers investors and analysts direct access to management commentary and company updates on Pacira’s non-opioid pain therapy commercial and development priorities.
Positive
- None.
Negative
- None.
News Market Reaction 5 Alerts
On the day this news was published, PCRX gained 2.73%, reflecting a moderate positive market reaction. Argus tracked a trough of -2.4% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $30M to the company's valuation, bringing the market cap to $1.12B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus 1 Up
Peers show mixed moves, with AMPH up 4.11%, COLL up 0.88%, DVAX up 0.19%, AVDL up 0.09%, and HROW down 2.37%, indicating stock-specific rather than broad sector momentum.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 30 | Board nomination | Neutral | +0.0% | Investor group announced intent to nominate three director candidates. |
| Dec 18 | Research collaboration | Positive | -2.5% | Joined PROBE Consortium to advance osteoarthritis research using large OA datasets. |
| Dec 03 | Inducement grants | Neutral | +0.5% | Granted 2,200 RSUs to new hires under inducement plan with time-based vesting. |
| Dec 02 | Clinical study data | Positive | +1.6% | 12‑month pilot showed better pain and function outcomes for iovera° vs RFA. |
| Nov 26 | Patent litigation | Neutral | -1.0% | Filed EXPAREL patent infringement lawsuits against two counterparties. |
Recent news has mostly aligned with modest price reactions, with one notable divergence on a positive consortium collaboration update.
Over the last several months, Pacira BioSciences issued diverse updates, including a director nomination effort on Dec. 30, 2025, joining the PROBE osteoarthritis consortium on Dec. 18, 2025, and inducement RSU grants on Dec. 1, 2025. A 12‑month iovera° pilot study readout on Dec. 2, 2025 showed significant pain and functional benefits, while EXPAREL patent litigation was disclosed on Nov. 26, 2025. Today’s conference presentation notice fits into a pattern of ongoing scientific, strategic, and corporate communications.
Market Pulse Summary
This announcement highlights Pacira BioSciences’ planned presentation at the 44th J.P. Morgan Healthcare Conference on January 14, 2026, with a live webcast and two-week replay. In context of recent clinical data, research collaborations, and governance and litigation updates, the conference slot offers another platform for management to communicate strategy and progress. Investors may watch for any new information shared during the presentation and how it relates to prior disclosures.
AI-generated analysis. Not financial advice.
BRISBANE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference at 11:15 AM PST (2:15 PM EST) on Wednesday, January 14, 2026. Live audio of the event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.
About Pacira
Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera®º, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing a pipeline of clinical-stage assets for musculoskeletal pain and adjacencies, its most advanced product candidate, PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy in Phase 2 clinical development for osteoarthritis of the knee. To learn more about Pacira, visit www.pacira.com.
Company Contact: Pacira BioSciences, Inc. Christian Pedetti (973) 254-4387 Christian.pedetti@pacira.com
FAQ
When will Pacira (PCRX) present at the J.P. Morgan Healthcare Conference in 2026?
How can I listen to Pacira (PCRX) live at the January 14, 2026 presentation?
Will Pacira (PCRX) provide a replay of the J.P. Morgan presentation?
What topics will Pacira (PCRX) cover in the January 14, 2026 presentation?
Is the Pacira (PCRX) J.P. Morgan presentation open to all investors?
